StockNews.com Initiates Coverage on Evogene (NASDAQ:EVGN)

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research report sent to investors on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners restated a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Trading Down 3.0 %

Shares of Evogene stock opened at $1.31 on Wednesday. The firm’s 50 day moving average is $1.48 and its 200 day moving average is $1.85. The firm has a market capitalization of $7.03 million, a PE ratio of -0.29 and a beta of 1.28. Evogene has a 1 year low of $1.20 and a 1 year high of $9.00.

Evogene (NASDAQ:EVGN) last issued its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. The firm had revenue of $1.61 million for the quarter, compared to analyst estimates of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same quarter last year, the business posted ($1.30) earnings per share.

Institutional Investors Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned 0.30% of Evogene as of its most recent filing with the Securities and Exchange Commission (SEC). 10.40% of the stock is owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.